Nirmatrelvir and ritonavir has been approved by the FDA for emergency use, treating mild to moderate COVID-19 in adults and children 12 and over who weigh more than 40 kg, who have tested positive for COVID-19 and are at high risk of hospitalization or death.
Nirmatrelvir and ritonavir are available as a generic combination medicine or under the brand name Paxlovid. This combination medication is only available via prescription. This means a written prescription from a licensed health care provider is required before purchase. In addition, nirmatrelvir and ritonavir are only prescribed after a patient has tested positive for COVID-19. These drugs cannot be used to prevent a COVID-19 infection.